PDB100 - Cost-Effectiveness of Exenatide Twice Daily (Bid) Added To Basal Insulin Compared To A Bolus Insulin Add-On In Turkey
Citation
Malhan, S., Güler, S., Yetkin, I., Baeten, S., & Verheggen, B. (2014). Cost-effectiveness of exenatide twice daily (bid) added to basal insulin compared to a bolus insulin add-on in Turkey. Value in Health, 17(7), A349.Abstract
Objectives
Type 2 diabetes (T2D) patients on basal insulin with uncontrolled HbA1c levels often receive an add-on with bolus insulin to lower HbA1c levels. The aim of this analysis is to estimate long-term cost-effectiveness of treating T2D patients with – a recently introduced – twice daily (BID) exenatide add-on to basal insulin strategy from a Turkish health care perspective.
